Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine Augmentation in Clozapine-resistant Schizophrenia
NCT00918021Phase 4Completed
- Sponsor
- Niuvanniemi Hospital
- Start
- Jun 2009
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in schizophrenia and schizoaffective disorder comparing placebo (A) with olanzapine (B) (2 arms). Primary endpoints: Global Assessment of Functioning at 24 weeks and Clinical Global Improvement Scale at 24 weeks. Started Jun 2009; status: completed.
02
Drugs
olanzapine
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00918021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00918021.